Migraine is a significant risk factor for postoperative nausea and vomiting, according to results of a retrospective study published in the Journal of Clinical Medicine. Migraine is a significant risk ...

Classification, Proposed Site of Action, Usual Dose, and Adverse Effects of Selected Antiemetic Drugs a b Pediatric doses should not exceed adult doses. c Most investigators administered ...

Please provide your email address to receive an email when new articles are posted on . Postoperative nausea and vomiting occurred in 18.2% of patients prescribed GLP-1s vs. 6% of patients in a ...

Please provide your email address to receive an email when new articles are posted on . Heron Therapeutics Inc. announced it has received FDA approval of Aponvie injectable emulsion, also known as HTX ...

A study from the July 2011 issue of Anesthesiology analyzed whether patients who experience post-operative nausea and vomiting have a genetic predisposition to the side effect, according to a Newswise ...

Postoperative nausea and vomiting (PONV) and pain remain some of the most significant dissatisfiers for surgical patients. During a recent session sponsored by Heron Therapeutics at Becker’s 22nd ...

Dexamethasone effectively reduces postoperative nausea for patients receiving neuraxial morphine for cesarean delivery and hysterectomy, according to a study in the April issue of Anesthesia & ...

Tetanic simulation applied to the P6 acupuncture point can reduce post-operative nausea and vomiting after a laparoscopic hysterectomy, according to a study published in the April 2011 issue of ...

Credit: Getty Images. HTX-019 is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant, a substance P/NK1 receptor antagonist, as a 30-second IV injection. A New ...

Purpose: The physiology, risk factors, and prevention and treatment of postoperative nausea and vomiting (PONV) are discussed. Summary: Factors to consider when determining a patient's risk for PONV ...

(RTTNews) - Heron Therapeutics, Inc. (HRTX) announced that FDA has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting or ...